SCHEMBL6891737

SCHEMBL6891737

CC(CCNCCCN)NCCCN

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.52
CA6 P23280 5/20 0.52
CA7 P43166 5/20 0.52
CA9 Q16790 5/20 0.52
CA14 Q9ULX7 5/20 0.52
CA5B Q9Y2D0 5/20 0.52
CA2 P00918 4/20 0.52
CA4 P22748 4/20 0.52
CA5A P35218 4/20 0.52
ALOX15 P16050 3/20 0.52
CASP2 P42575 2/20 0.52
F13A1 P00488 2/20 0.52
CYP1A2 P05177 2/20 0.52
THPO P40225 2/20 0.52
MEN1 O00255 2/20 0.52
RECQL P46063 2/20 0.52
KMT2A Q03164 2/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CA3 P07451 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25003626 0.98 CA12 (0.50) CA12CA6CA7CA9CA14
SCHEMBL6217773 0.93 CA12 (0.50) CA12CA6CA7CA9CA14
SCHEMBL14163416 0.91 CA12 (0.48) CA12CA6CA7CA9CA14
SCHEMBL6220142 0.86 CA12 (0.38) CA12CA6CA7CA9CA14
SCHEMBL16335714 0.86 CA12 (0.50) CA12CA6CA7CA9CA14
SCHEMBL11309907 0.86 CA12 (0.38) CA12CA6CA7CA9CA14
SCHEMBL18917151 0.85 CA12 (0.50) CA12CA6CA7CA9CA14
SCHEMBL14163417 0.85 CA12 (0.50) CA12CA6CA7CA9CA14
SCHEMBL1961496 0.83 RELA (0.46) CA12CA6CA7CA9CA14
SCHEMBL16260099 0.83 CA12 (0.48) CA12CA6CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040232073-A1 Bulk separation of semiconducting and metallic single wall nanotubes NATIONAL SCIENCE FOUNDATION 2004-11-25 US claimed
WO-2004082794-A2 BULK SEPARATION OF SEMICONDUCTING AND METALLIC SINGLE WALL NANOTUBES UNIVERSITY OF CONNECTICUT (US) 2004-09-30 WO claimed
EP-4660368-A1 AMINO GROUP-CONTAINING FIBER, MANUFACTURING METHOD FOR SAME, ARTICLE USING SAID FIBER, MOLDING, CARBON DIOXIDE ADSORPTION MATERIAL INCLUDING SAME, USE METHOD FOR CARBON DIOXIDE ADSORPTION MATERIAL, AND CARBON DIOXIDE SEPARATION/RECOVERY DEVICE Toyobo Co., Ltd. (JP) 2025-12-10 EP disclosed
WO-2024162439-A1 AMINO GROUP-CONTAINING FIBER, MANUFACTURING METHOD FOR SAME, ARTICLE USING SAID FIBER, MOLDING, CARBON DIOXIDE ADSORPTION MATERIAL INCLUDING SAME, USE METHOD FOR CARBON DIOXIDE ADSORPTION MATERIAL, AND CARBON DIOXIDE SEPARATION/RECOVERY DEVICE 東洋紡株式会社 2024-08-08 WO disclosed
EP-2990503-B1 METHOD OF FORMING METAL FILM FLOSFIA INC (JP) 2022-01-12 EP disclosed
US-9828694-B2 Method of forming metal film FLOSFIA INC. (JP) 2017-11-28 US disclosed
US-20160060788-A1 METHOD OF FORMING METAL FILM FLOSFIA INC. (JP) 2016-03-03 US disclosed
EP-2990503-A1 METHOD OF FORMING METAL FILM Flosfia Inc. (JP) 2016-03-02 EP disclosed
US-8148577-B2 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2012-04-03 US disclosed
US-8148577-B2 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2012-04-03 US disclosed
US-20100273745-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2010-10-28 US disclosed
US-20100273745-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2010-10-28 US disclosed
US-20070208082-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS JOHN HOPKINS UNIVERSITY (US) 2007-09-06 US disclosed
US-20070208082-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS JOHN HOPKINS UNIVERSITY (US) 2007-09-06 US disclosed
WO-2007021839-A2 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS JOHNS HOPKINS UNIVERSITY (US) 2007-02-22 WO disclosed
US-20040232073-A1 Bulk separation of semiconducting and metallic single wall nanotubes NATIONAL SCIENCE FOUNDATION 2004-11-25 US disclosed
WO-2004082794-A2 BULK SEPARATION OF SEMICONDUCTING AND METALLIC SINGLE WALL NANOTUBES UNIVERSITY OF CONNECTICUT (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208082-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS KDM1A, JMJD6, SRM CA12 4412/4885CA6 3330/4885CA7 3595/4885
US-20100273745-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS KDM1A, JMJD6, SRM CA12 4412/4885CA6 3330/4885CA7 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.